变应性鼻炎患者血清可溶性Fas与Fas配体的变化

Changes on serum solubility of Fas and FasL on patients with allergic rhinitis

目的 研究变应性鼻炎患者血清可溶性Fas(sFas)和Fas配体 (sFasL)的变化。方法 采用双抗体酶联免疫吸附法 (ELISA)检测正常对照组 19例 ,变应性鼻炎患者免疫治疗前 31例 ,免疫治疗后 11例的血清sFas和sFasL及总IgE(TIgE)的水平。结果 变应性鼻炎患者免疫治疗前sFas水平较正常对照组低P <0 .0 5 ;sFasL的水平与正常对照组相比则无显著性差异 ,P >0 .0 5。而变应性鼻炎患者免疫治疗前后血清sFas的水平相比 ,无显著性差异 ,P >0 .0 5 ;但免疫治疗后患者血清sFasL的水平比免疫治疗前明显降低 ,存在显著性差异 ,P <0 .0 5。sFas与tIgE无显著性相关 ,sFasL与tIgE则呈显著性相关。

Objective To study the changes of serum solubility of Fas(sFas) and FasL(sFasL) on patients with allergic rhinitis. Methods The adsorbing methods of double antibody enzyme immunity (ELISA) was used to detect the general level of IgE (tIgE) and serum sFas and sFasL in 19 cases of control group, 31 cases of patient with allergic rhinitis pre immunity treatment, and 11 cases post immunity treatment. Results The levels of sFas on pre immune treatment patients were significantly reduced as compared to normal control ( P <0.05), while the levels of sFasL were not significant different ( P >0.05) in the two groups. On the other hand, the levels of sFas were similar in pre and post immune treatment patients ( P >0.05). However, the reduction of sFasL in post immune treatment patients was more obvious than that in pre immune treatment patients ( P <0.05). Conclusion Cell apoptosis caused by Fas and FasL is involved in the process of allergic rhinitis.